Marijuana Use Linked to Improved Acute-HF Hospital Survival Marijuana Use Linked to Improved Acute-HF Hospital Survival
Chronic cannabis use seemed to protect against in-hospital death and shorten length of stay in the observational study with propensity matching — but not in all types of heart failure.Medscape Medical News
ConclusionType D personality was not significantly associated with increased risk of all-cause mortality or cardiovascular death in patients with non-ischemic HF.
At present, there are no unanimous criteria of surgical indications for Takayasu arteritis (TA) patients, although ischemic symptoms of organs or limbs and aneurysms at risk of rupture may be widely in consensus. However, because heart failure has been proved to be a leading cause of death in TA patients, abnormal hemodynamics should also be considered a surgical indication to ease the burden on the heart and to improve patients ’ prognoses.
AbstractPurpose of ReviewThe purpose of this review is to synthesize and summarize recent developments in the care of patients with end-stage heart failure being managed with a left ventricular assist device (LVAD) as destination therapy.Recent FindingsAlthough the survival of patients treated with LVAD continues to improve, the rates of LVAD-associated complication, such as right ventricular failure, bleeding complications, and major infection, remain high, and management of these patients remains challenging.SummaryThe durability and hemocompatibility of LVAD support have greatly increased in recent years as a result of ...
Authors: De Vecchis R, Paccone A, Di Maio M Abstract BACKGROUND: Clinical efficacy of sacubitril/ valsartan - administered for the recommended indication of patients with reduced(
Conclusions: The models developed using insurance claims data could reliably predict the risk of MACRO in patients with T2DM and enabled patients at higher-risk of DKD to be identified in the absence of baseline diabetic nephropathy, CKD, or proteinuria. These models could help establish strategies to reduce the risk of MACRO in T2DM patients. PMID: 31625766 [PubMed - as supplied by publisher]
This study enrolled 32 heart failure patients and 28 control subjects. Total cfDNA levels were not different between groups (P=0.343). Bisulfite-digital PCR using unmethylated FAM101A locus demonstrated cardiomyocyte-specific cfDNA was significantly elevated in heart failure patients compared to controls (median 0.99 [IQR, 0.77-1.98] vs 0 [0-0.91] copies/mL, P=0.003). Cardiomyocyte-specific cfDNA significantly discriminated heart failure from controls (AUC, 0.716, P=0.003), and was positively correlated with troponin I (r=0.438, P=0.003) but not with B-type natriuretic peptide (r=0.275, P=0.058). cfDNA may be a novel bioma...
Authors: Walsh JL, AlJaroudi WA, Lamaa N, Abou Hassan OK, Jalkh K, Elhajj IH, Sakr G, Isma'eel H Abstract Objectives. In heart failure, invasive angiography is often employed to differentiate ischaemic from non-ischaemic cardiomyopathy. We aim to examine the predictive value of echocardiographic strain features alone and in combination with other features to differentiate ischaemic from non-ischaemic cardiomyopathy, using artificial neural network (ANN) and logistic regression modelling. Design. We retrospectively identified 204 consecutive patients with an ejection fraction
ConclusionsRisk stratification for cardiac amyloidosis with the newly developed “HeiRisk” score may be superior to other staging systems for patients with advanced heart failure due to amyloid cardiomyopathy.
We created a translational model of chronic heart failure in rats that developed in 3 months after reproducing experimental anterior transmural myocardial infarction. The model simulated the basic clinicodiagnostic criteria of this disease: impaired contractility and dilatation of heart ventricles, signs of venous congestion, elevated plasma content of biochemical markers, and abnormal overexpression of AT1aR and β-adrenoceptors.
Transthyretin amyloidosis can be either the wild-type (ATTR-wt) or the hereditary form (ATTR-m) with autosomal dominant inheritance. ATTR seems to be an underdiagnosed disease, despite now being recognized as one of the most frequent causes of heart failure (HF) with preserved ejection fraction. The confirmation of diagnosis includes a genetic analysis as a critical step to distinguish between ATTR-wt and hereditary amyloidosis. The present study aimed to evaluate the potential application of High-Resolution Melting (HRM) analysis for identifying gene mutations in patients with suspected ATTR-m.